BTIG Downgrades Oncocyte to Neutral Following News of CEO Departure
In an announcement late Wednesday, the company said Ronnie Andrews had stepped down, marking the firm's third major executive to depart in recent months.
Canaccord Downgrades T2 Biosystems to Hold
The investment bank cited a soft Q3 outlook, slower-than-expected pipeline progress, and capital and liquidity concerns raised in the company's preliminary quarterly results.
UBS, JP Morgan Downgrade Singular Genomics to Neutral
Analysts for the two banks cited supply chain and manufacturing issues that have delayed the launch of the G4 sequencing instrument as key reasons for the downgrade.
Cowen Downgrades Invitae to Market Perform
According to Cowen analysts, Invitae's restructuring is a step in the right direction towards positive cash flow but changes nothing materially.
Evercore ISI Downgrades PerkinElmer Shares to In Line
The bank previously had an Outperform Rating on PerkinElmer, and it also lowered its price target for the firm's stock to $150 per share from $175 per share.